Amgen Inc. $AMGN Stock: Global Wealth Management Investment Advisory Inc. Decreases Stake

Global Wealth Management Investment Advisory Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 9.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,081 shares of the medical research company’s stock after selling 1,620 shares during the quarter. Global Wealth Management Investment Advisory Inc.’s holdings in Amgen were worth $6,357,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of AMGN. 71 West Capital Partners increased its position in shares of Amgen by 7.9% during the third quarter. 71 West Capital Partners now owns 3,914 shares of the medical research company’s stock worth $1,650,000 after acquiring an additional 288 shares in the last quarter. Pinion Investment Advisors LLC acquired a new stake in shares of Amgen in the 3rd quarter worth about $207,000. Leuthold Group LLC raised its holdings in shares of Amgen by 9.2% in the 3rd quarter. Leuthold Group LLC now owns 22,409 shares of the medical research company’s stock worth $9,446,000 after acquiring an additional 1,897 shares during the last quarter. Fulcrum Asset Management LLP lifted its position in Amgen by 65.5% in the 3rd quarter. Fulcrum Asset Management LLP now owns 4,428 shares of the medical research company’s stock valued at $1,876,000 after acquiring an additional 1,752 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in Amgen by 16.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 112,799 shares of the medical research company’s stock valued at $45,940,000 after acquiring an additional 16,327 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
• Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
• Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen’s new drug could mean fewer shots for obesity patients
• Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
• Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on AMGN shares. Barclays lifted their price target on Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 21st. Weiss Ratings raised Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. TD Cowen increased their price objective on Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Freedom Broker lowered Amgen from a “buy” rating to a “hold” rating and raised their target price for the company from $450.00 to $470.00 in a report on Friday. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $410.00 target price on shares of Amgen in a research report on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $422.76.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is owned by insiders.

Amgen Stock Performance

Shares of AMGN stock opened at $465.23 on Tuesday. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.13. The firm has a 50-day moving average of $423.08 and a 200-day moving average of $378.80. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The company has a market cap of $251.52 billion, a P/E ratio of 26.99, a P/E/G ratio of 3.47 and a beta of 0.43.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. During the same period in the previous year, the company earned $5.64 earnings per share. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. Equities research analysts forecast that Amgen Inc. will post 23.33 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. Amgen’s dividend payout ratio (DPR) is currently 58.47%.

Amgen Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.